Price
Financials
Consolidated, Rs crore| Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 40 | 38 | 52 | 52 | 53 | 47 | 37 | 60 |
| Expenses | 36 | 34 | 47 | 48 | 48 | 35 | 33 | 50 |
| Operating Profit | 3 | 4 | 4 | 4 | 4 | 12 | 4 | 10 |
| OPM % | 9% | 10% | 9% | 8% | 8% | 26% | 10% | 17% |
| Other Income | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 |
| Profit before tax | 2 | 2 | 2 | 2 | 3 | 9 | 3 | 5 |
| Tax % | 49% | 34% | 45% | -34% | 30% | 13% | 23% | 31% |
| Net Profit | 2 | 1 | 2 | 3 | 2 | 6 | 2 | 3 |
| EPS in Rs | 6.78 | 1.64 | 1.57 | 2.31 | 1.73 | 5.53 | 2.22 | 3.00 |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 29 | 49 | 77 | 104 | 97 | 101 |
| Expenses | 27 | 47 | 70 | 95 | 83 | 83 |
| Operating Profit | 2 | 1 | 7 | 9 | 14 | 18 |
| OPM % | 7% | 3.0% | 10% | 8% | 14% | 18% |
| Other Income | 0 | 0 | 1 | 0 | 4 | 0 |
| Interest | 0 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 3 | 2 | 3 | 4 | 5 |
| Profit before tax | 0 | -2 | 4 | 4 | 11 | 9 |
| Tax % | 75% | 15% | 42% | 10% | 17% | 28% |
| Net Profit | 0 | -2 | 2 | 4 | 9 | 6 |
| EPS in Rs | 0.39 | -10.30 | 3.58 | 3.87 | 7.27 | 5.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 4% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 16% | 10% | 4% | ||
| Compounded Profit Growth | % | 35% | 31% | -25% | ||
| Stock Price CAGR | % | % | -10% | -21% | ||
| Return on Equity | % | % | 13% | 10% |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 42 | 48 |
| Borrowings | 13 | 17 | 22 | 25 | 44 | 38 |
| Other Liabilities | 14 | 15 | 32 | 35 | 27 | 37 |
| Total Liabilities | 30 | 35 | 74 | 105 | 124 | 133 |
| Fixed Assets | 16 | 17 | 26 | 36 | 49 | 50 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 2 |
| Investments | 0 | 0 | 0 | 2 | 4 | 3 |
| Other Assets | 14 | 18 | 48 | 63 | 72 | 79 |
| Total Assets | 30 | 35 | 74 | 105 | 124 | 133 |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -0 | 8 | -16 | -4 | 17 |
| Cash from Investing Activity | -12 | -3 | -12 | -20 | -14 | -7 |
| Cash from Financing Activity | 11 | 3 | 13 | 29 | 16 | -10 |
| Net Cash Flow | -0 | -0 | 10 | -6 | -2 | -0 |
| Free Cash Flow | -10 | -3 | 0 | -34 | -16 | 9 |
| CFO/OP | 17% | 8% | 134% | -168% | -26% | 106% |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 | 128 | 119 |
| Inventory Days | 40 | 45 | 87 | 83 | 108 | 153 |
| Days Payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 | 136 | 118 |
| Working Capital Days | -79 | -44 | -40 | 47 | 63 | 65 |
| ROCE % | -5% | 10% | 15% | 13% |
| Apr 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% | 72.85% |
| FIIs | 12.88% | 8.51% | 8.99% | 8.88% | 15.12% | 16.14% | 16.79% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.68% | 0.00% | 0.00% |
| Public | 14.27% | 18.64% | 18.16% | 18.27% | 11.35% | 11.01% | 10.36% |
| No. of Shareholders | 784 | 255 | 245 | 251 | 243 | 240 | 221 |
Fundamentals
Market Cap₹ 99.5 Cr.
Current Price₹ 90.0
Stock P/E17.2
Book Value₹ 53.3
ROCE12.6 %
ROE10.3 %
Dividend Yield0.22 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)4%
Compounded Profit Growth (TTM)-25%
Consolidated figures.
Valuation
Market capRs 100 Cr
Enterprise valueRs 116 Cr
Price to book39.96x
Price to sales2.04x
EV / EBITDA74.12x
EV / sales2.38x
Earnings yield-2.38%
Profitability
Operating margin (excl. other income)2.99%
Operating margin (incl. other income)3.21%
EBITDA margin3.21%
Pre-tax margin-4.20%
Net profit margin-4.85%
ROE-85.41%
ROCE-5.65%
ROA-7.28%
ROIC (approx.)-6.07%
Tax rate-15.12%
Other income / net worth4.42%
Growth
Sales growth (latest year)70.77%
Profit growth (latest year)-2733.33%
Per share
EPS (TTM)Rs -2.14
EPS (latest year)Rs -10.30
Book value per shareRs 2.25
Sales per shareRs 44.20
Cash flow per shareRs -0.28
Free cash flow per shareRs 8.14
Efficiency
Asset turnover1.41x
Fixed asset turnover2.95x
Inventory turnover8.84x
Inventory days41 days
Debtor days44 days
Debtors turnover8.31x
Creditor days154 days
Cash conversion cycle118 days
Working capital days65 days
Leverage
Total debtRs 17 Cr
Cash and bankRs 0 Cr
Net debtRs 17 Cr
Debt to equity6.88x
Net debt / EBITDA10.74x
Interest coverage-0.99x
Owners' fund to total sources7.18%
Debt to assets49.37%
Cash flow
Cash from Operating Activity (latest year)Rs -0 Cr
Cash from Investing Activity (latest year)Rs -3 Cr
Cash from Financing Activity (latest year)Rs 3 Cr
Net Cash Flow (latest year)Rs -0 Cr
Free cash flow (latest year)Rs 9 Cr
FCFE (approx.: FCF + change in debt)Rs 13 Cr
Cash from ops / profit, 5 years0.26x
Statement figures
Net sales (TTM)Rs 49 Cr
Net sales (latest year)Rs 49 Cr
Operating profit excl. other income (latest year)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 2 Cr
PBDT (TTM)Rs 1 Cr
Profit before tax (TTM)Rs -2 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -2 Cr
Net profit (latest year)Rs -2 Cr
Depreciation (TTM)Rs 3 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 43 Cr
Total expenditure (latest year)Rs 47 Cr
Total income (latest year)Rs 49 Cr
Share capitalRs 2 Cr
ReservesRs 0 Cr
Shareholders' fundsRs 2 Cr
Total assetsRs 35 Cr
Net blockRs 17 Cr
InvestmentsRs 0 Cr
ReceivablesRs 6 Cr
InventoryRs 5 Cr
Other liabilitiesRs 15 Cr
Shares outstanding (crore)1.11
Ownership
Promoter holding72.85% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | SOTAC | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -5.3% | -2.8% | -2.5 pts |
| 1 month | -15.0% | -6.8% | -8.3 pts |
| 3 months | -26.5% | -7.6% | -18.9 pts |
| 6 months | -21.0% | +0.4% | -21.4 pts |
| 1 year | -21.0% | -9.9% | -11.1 pts |
| 3 years | -27.4% | +14.2% | -41.6 pts |
Red flags
F-score 3 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹60 Cr +15.4% vs Mar 2024.
Net profit ₹3 Cr +0.0%.
Against our estimate for Mar 2026: sales +59.4%, profit +42.6% beat.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 daysMandatory Market making period in SME scrip is overSME scrip is not regularly traded
Quick answers
What is the market cap of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd (SOTAC) has a market capitalisation of Rs 99.5 Cr. at the 2026-10-01 close.
What is the P/E ratio of Sotac Pharmaceuticals Ltd?
Sotac Pharmaceuticals Ltd trades at a P/E of 17.2 on trailing twelve-month profit, at the 2026-10-01 close.
What were Sotac Pharmaceuticals Ltd's latest quarterly results?
In the Mar 2026 quarter, Sotac Pharmaceuticals Ltd sales was Rs 60 Cr (+15.4% vs Mar 2024) and net profit was Rs 3 Cr.
What is the 52-week high and low of Sotac Pharmaceuticals Ltd?
The 52-week high is Rs 139.65 and the 52-week low is Rs 86.00.